Antimicrobial properties of lactoferrin

Biochimie

Volumn 91, Issue 1, 2009, Pages 19-29

  Jenssen, Håvard ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibacterial; Antifungal; Antiparasitic; Antiviral; Lactoferrin

Indexed keywords

LACTOFERRIN;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; LACTOFERRIN;

MAMMALIA;

EID: 58149113170     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2008.05.015     Document Type: Review

References (171)

1. Hancock R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1 3 (2001) 156-164
2. Brogan T.D., et al. Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis. Thorax. 30 1 (1975) 72-79
3. Lim D.J., et al. Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 19 Suppl. 1 (2000) S17-S25
4. Baker E.N., and Baker H.M. Molecular structure, binding properties and dynamics of lactoferrin. Cell. Mol. Life Sci. 62 22 (2005) 2531-2539
5. Haurum J.S., et al. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids 7 10 (1993) 1307-1313
6. Benne C.A., et al. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J. Infect. Dis. 171 2 (1995) 335-341
7. Brock J. Lactoferrin: a multifunctional immunoregulatory protein?. Immunol. Today 16 9 (1995) 417-419
8. Brock J.H. The physiology of lactoferrin. Biochem. Cell Biol. 80 1 (2002) 1-6
9. Ward P.P., Uribe-Luna S., and Conneely O.M. Lactoferrin and host defense. Biochem. Cell Biol. 80 1 (2002) 95-102
10. Valenti P., and Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell. Mol. Life Sci. 62 22 (2005) 2576-2587
11. Kai K., et al. Lactoferrin stimulates a Staphylococcus aureus killing activity of bovine phagocytes in the mammary gland. Microbiol. Immunol. 46 3 (2002) 187-194
12. Bullen J.J., Rogers H.J., and Leigh L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br. Med. J. 1 792 (1972) 69-75
13. Arnold R.R., Cole M.F., and McGhee J.R. A bactericidal effect for human lactoferrin. Science 197 4300 (1977) 263-265
14. Farnaud S., and Evans R.W. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol. Immunol. 40 7 (2003) 395-405
15. Florisa R., et al. Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr. Pharm. Des. 9 16 (2003) 1257-1275
16. Beaumont S.L., Maggs D.J., and Clarke H.E. Effects of bovine lactoferrin on in vitro replication of feline herpesvirus. Vet. Ophthalmol. 6 3 (2003) 245-250
17. Berkhout B., et al. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. 55 2 (2002) 341-355
18. Drobni P., Naslund J., and Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res. 64 1 (2004) 63-68
19. Hara K., et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res. 24 3 (2002) 228
20. Hasegawa K., et al. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol. 47 2 (1994) 73-85
21. Ikeda M., et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 66 1 (2000) 51-63
22. Lin T.Y., Chu C., and Chiu C.H. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 186 8 (2002) 1161-1164
23. Marchetti M., et al. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29 2-3 (1996) 221-231
24. Marchetti M., et al. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. Biometals 11 2 (1998) 89-94
25. Puddu P., et al. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol. 30 9 (1998) 1055-1062
26. Superti F., et al. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim. Biophys. Acta 1528 2-3 (2001) 107-115
27. Tanaka T., et al. Antiviral activity of lactoferrin against canine herpesvirus. Antiviral Res. 60 3 (2003) 193-199
28. van der Strate B.W., et al. Antiviral activities of lactoferrin. Antiviral Res. 52 3 (2001) 225-239
29. Arnold D., et al. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res. 53 2 (2002) 153-158
30. Marchetti M., et al. Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med. Microbiol. Immunol. (Berl.) 187 4 (1999) 199-204
31. Seganti L., et al. Antiviral activity of lactoferrin towards naked viruses. Biometals 17 3 (2004) 295-299
32. Andersen J.H., et al. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51 2 (2001) 141-149
33. Fujihara T., and Hayashi K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch. Virol. 140 8 (1995) 1469-1472
34. Harmsen M.C., et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172 2 (1995) 380-388
35. Ikeda M., et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun. 245 2 (1998) 549-553
36. Murphy M.E., et al. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol. 145 8 (2000) 1571-1582
37. Portelli J., Gordon A., and May J.T. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J. Med. Microbiol. 47 11 (1998) 1015-1018
38. Swart P.J., et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res. Hum. Retroviruses 12 9 (1996) 769-775
39. Yi M., et al. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol. 71 8 (1997) 5997-6002
40. Suzuki Y.A., Lopez V., and Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell. Mol. Life Sci. 62 22 (2005) 2560-2575
41. Kirkpatrick C.H., et al. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis. 124 6 (1971) 539-544
42. Soukka T., Tenovuo J., and Lenander-Lumikari M. Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol. Lett. 69 3 (1992) 223-228
43. Weinberg G.A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob. Agents Chemother. 38 5 (1994) 997-1003
44. Arnold R.R., Brewer M., and Gauthier J.J. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect. Immun. 28 3 (1980) 893-898
45. Kalmar J.R., and Arnold R.R. Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect. Immun. 56 10 (1988) 2552-2557
46. Yamauchi K., et al. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 61 2 (1993) 719-728
47. Arnold R.R., et al. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect. Immun. 32 2 (1981) 655-660
48. Dalmastri C., et al. Enhanced antimicrobial activity of lactoferrin by binding to the bacterial surface. Microbiologica 11 3 (1988) 225-230
49. Bortner C.A., Arnold R.R., and Miller R.D. Bactericidal effect of lactoferrin on Legionella pneumophila: effect of the physiological state of the organism. Can. J. Microbiol. 35 11 (1989) 1048-1051
50. Baker E.N., Baker H.M., and Kidd R.D. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem. Cell Biol. 80 1 (2002) 27-34
51. Appelmelk B.J., et al. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62 6 (1994) 2628-2632
52. Brandenburg K., et al. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol. Chem. 382 8 (2001) 1215-1225
53. Shahriar F., Gordon J.R., and Simko E. Identification of lipopolysaccharide-binding proteins in porcine milk. Can. J. Vet. Res. 70 4 (2006) 243-250
54. Ellison III R.T., Giehl T.J., and LaForce F.M. Damage of the outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56 11 (1988) 2774-2781
55. Nikaido H., and Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol. Rev. 49 1 (1985) 1-32
56. 2+. J. Gen. Microbiol. 136 7 (1990) 1437-1446
57. 2+ binding to bovine lactoferrin enhances protein stability and influences the release of bacterial lipopolysaccharide. Biochem. Cell Biol. 80 1 (2002) 41-48
58. Weinberg E.D. Human lactoferrin: a novel therapeutic with broad spectrum potential. J. Pharm. Pharmacol. 53 10 (2001) 1303-1310
59. Vorland L.H. Lactoferrin: a multifunctional glycoprotein. APMIS 107 11 (1999) 971-981
60. Ellison III R.T., and Giehl T.J. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88 4 (1991) 1080-1091
61. Singh P.K., et al. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am. J. Physiol. Lung Cell. Mol. Physiol. 279 5 (2000) L799-L805
62. Leitch E.C., and Willcox M.D. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J. Med. Microbiol. 48 9 (1999) 867-871
63. Zimecki M., et al. The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice. Postepy Hig. Med. Dosw. (Online). 62 (2008) 42-46
64. Weber-Dabrowska B., et al. Alternative therapies in antibiotic-resistant infection. Adv. Med. Sci. 51 (2006) 242-244
65. Qiu J., et al. Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc. Natl. Acad. Sci. U.S.A. 95 21 (1998) 12641-12646
66. Hendrixson D.R., et al. Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol. Microbiol. 47 3 (2003) 607-617
67. Blocker A., et al. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J. Cell Biol. 147 3 (1999) 683-693
68. Buttner D., and Bonas U. Port of entry-the type III secretion translocon. Trends Microbiol. 10 4 (2002) 186-192
69. Feldman M.F., and Cornelis G.R. The multitalented type III chaperones: all you can do with 15 kDa. FEMS Microbiol. Lett. 219 2 (2003) 151-158
70. Jarvis K.G., et al. Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc. Natl. Acad. Sci. U.S.A. 92 17 (1995) 7996-8000
71. Kaniga K., Trollinger D., and Galan J.E. Identification of two targets of the type III protein secretion system encoded by the inv and spa loci of Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. J. Bacteriol. 177 24 (1995) 7078-7085
72. Gomez H.F., et al. Human lactoferrin impairs virulence of Shigella flexneri. J. Infect. Dis. 187 1 (2003) 87-95
73. Ochoa T.J., and Clearly T.G. Lactoferrin disruption of bacterial type III secretion systems. Biometals 17 3 (2004) 257-260
74. Ochoa T.J., Noguera-Obenza M., and Cleary T.G. Lactoferrin blocks the initial host cell attachment mechanism of enteropathogenic E. coli (EPEC). Adv. Exp. Med. Biol. 554 (2004) 463-466
75. Ochoa T.J., et al. Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect. Immun. 71 9 (2003) 5149-5155
76. Bessler H.C., de Oliveira I.R., and Giugliano L.G. Human milk glycoproteins inhibit the adherence of Salmonella typhimurium to HeLa cells. Microbiol. Immunol. 50 11 (2006) 877-882
77. Ling J.M., and Schryvers A.B. Perspectives on interactions between lactoferrin and bacteria. Biochem. Cell Biol. 84 3 (2006) 275-281
78. Odeh R., and Quinn J.P. Problem pulmonary pathogens: Pseudomonas aeruinosa. Semin. Respir. Crit. Care Med. 21 4 (2000) 331-339
79. Singh P.K., et al. A component of innate immunity prevents bacterial biofilm development. Nature 417 6888 (2002) 552-555
80. Caraher E.M., et al. The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms. J. Antimicrob. Chemother. 60 3 (2007) 546-554
81. Leitch E.C., and Willcox M.D. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Curr. Eye Res. 19 1 (1999) 12-19
82. Weinberg E.D. Suppression of bacterial biofilm formation by iron limitation. Med. Hypotheses 63 5 (2004) 863-865
83. Berlutti F., et al. Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int. J. Immunopathol. Pharmacol. 18 4 (2005) 661-670
84. Lewis L.A., et al. Identification and molecular analysis of lbpBA, which encodes the two-component meningococcal lactoferrin receptor. Infect. Immun. 66 6 (1998) 3017-3023
85. Pettersson A., et al. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol. Microbiol. 27 3 (1998) 599-610
86. Ekins A., et al. Lactoferrin receptors in Gram-negative bacteria: insights into the iron acquisition process. Biometals 17 3 (2004) 235-243
87. Hammerschmidt S., et al. Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect. Immun. 67 4 (1999) 1683-1687
88. Shaper M., et al. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect. Immun. 72 9 (2004) 5031-5040
89. Dhaenens L., Szczebara F., and Husson M.O. Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect. Immun. 65 2 (1997) 514-518
90. de Bortoli N., et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol. 102 5 (2007) 951-956
91. Bergamaschi A., Magrini A., and Pietroiusti A. Recent advances in the treatment of Helicobacter pylori infection, Recent Patents Anti-Infect. Drug Disc. 2 3 (2007) 197-205
92. Tursi A., et al. Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med. Sci. Monit. 13 4 (2007) CR187-CR190
93. Erdei J., Forsgren A., and Naidu A.S. Lactoferrin binds to porins OmpF and OmpC in Escherichia coli. Infect. Immun. 62 4 (1994) 1236-1240
94. Tryon V.V., and Baseman J.B. The acquisition of human lactoferrin by Mycoplasma pneumoniae. Microb. Pathog. 3 6 (1987) 437-443
95. Anderson J.E., et al. Opposing selective forces for expression of the gonococcal lactoferrin receptor. Mol. Microbiol. 48 5 (2003) 1325-1337
96. Prinz T., and Tommassen J. Association of iron-regulated outer membrane proteins of Neisseria meningitidis with the RmpM (class 4) protein. FEMS Microbiol. Lett. 183 1 (2000) 49-53
97. Vogel L., et al. Human lactoferrin receptor activity in non-encapsulated Haemophilus influenzae. FEMS Microbiol. Lett. 156 1 (1997) 165-170
98. Geertsema R.S., Kimball R.A., and Corbeil L.B. Bovine plasma proteins increase virulence of Haemophilus somnus in mice. Microb. Pathog. 42 1 (2007) 22-28
99. Kim C.M., et al. Vibrio vulnificus metalloprotease VvpE is essentially required for swarming. FEMS Microbiol. Lett. 269 1 (2007) 170-179
100. Andersen J.H., et al. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol. 74 2 (2004) 262-271
101. Jenssen H. Anti herpes simplex virus activity of lactoferrin/lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. Cell. Mol. Life Sci. 62 24 (2005) 3002-3013
102. Berkhout B., et al. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 17 3 (2004) 291-294
103. Superti F., et al. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol. (Berl.) 186 2-3 (1997) 83-91
104. Pietrantoni A., et al. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob. Agents Chemother 47 8 (2003) 2688-2691
105. Waarts B.L., et al. Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate. Virology 333 2 (2005) 284-292
106. Viani R.M., et al. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. Aids 13 10 (1999) 1273-1274
107. Andersen J.H., Jenssen H., and Gutteberg T.J. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58 3 (2003) 209-215
108. Jenssen H., et al. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res. 64 2 (2004) 119-126
109. Kaito M., et al. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J. Gastroenterol. Hepatol. 22 11 (2007) 1894-1897
110. Zuccotti G.V., et al. Modulation of innate and adaptive immunity by lactoferrin in human immunodeficiency virus (HIV)-infected, antiretroviral therapy-naive children. Int. J. Antimicrob. Agents 29 3 (2007) 353-355
111. Rochard E., et al. Characterization of lactotransferrin receptor in epithelial cell lines from non-malignant human breast, benign mastopathies and breast carcinomas. Anticancer Res. 12 6B (1992) 2047-2051
112. Jenssen H., et al. The anti-HSV mode of action to lactoferrin and lactoferricin. Antiviral Res. 79 3 (2008) 192-198
113. Kolset S.O., and Gallagher J.T. Proteoglycans in haemopoietic cells. Biochim. Biophys. Acta 1032 2-3 (1990) 191-211
114. Iozzo R.V., and Murdoch A.D. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J. 10 5 (1996) 598-614
115. Bernfield M., et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8 (1992) 365-393
116. Trybala E., et al. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res. 62 3 (2004) 125-134
117. Parker K.H., Winlove C.P., and Maroudas A. The theoretical distributions and diffusivities of small ions in chondroitin sulphate and hyaluronate. Biophys. Chem. 32 2-3 (1988) 271-282
118. Iida J., et al. A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J. Biol. Chem. 273 10 (1998) 5955-5962
119. Pettersson I., et al. Biosynthesis of heparin. Purification of a 110-kDa mouse mastocytoma protein required for both glucosaminyl N-deacetylation and N-sulfation. J. Biol. Chem. 266 13 (1991) 8044-8049
120. DiGabriele A.D., et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393 6687 (1998) 812-817
121. Kjellen L., and Lindahl U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60 (1991) 443-475
122. Lustig F., et al. Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans. Biochemistry 35 37 (1996) 12077-12085
123. Camejo E.H., et al. Interferon gamma binds to extracellular matrix chondroitin-sulfate proteoglycans, thus enhancing its cellular response. Arterioscler. Thromb. Vasc. Biol. 15 9 (1995) 1456-1465
124. Hoogewerf A.J., et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36 44 (1997) 13570-13578
125. Lookene A., Savonen R., and Olivecrona G. Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique. Biochemistry 36 17 (1997) 5267-5275
126. Olsson U., et al. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler. Thromb. Vasc. Biol. 17 1 (1997) 149-155
127. Mettenleiter T.C. Brief overview on cellular virus receptors. Virus Res. 82 1-2 (2002) 3-8
128. Spillmann D. Heparan sulfate: anchor for viral intruders?. Biochimie 83 8 (2001) 811-817
129. Jenssen H., et al. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 61 2 (2004) 101-109
130. Mann D.M., Romm E., and Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269 38 (1994) 23661-23667
131. Shimazaki K., et al. Properties of a heparin-binding peptide derived from bovine lactoferrin. J. Dairy Sci. 81 11 (1998) 2841-2849
132. Wu H.F., Monroe D.M., and Church F.C. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys. 317 1 (1995) 85-92
133. Marchetti M., et al. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318 1 (2004) 405-413
134. Herold B.C., et al. Differences in the susceptibility of Herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J. Virol. 70 6 (1996) 3461-3469
135. M. Marchetti, M.G. Ammendolia, F. Superti, Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin, Biochimie (this issue).
136. Gerber S.I., Belval B.J., and Herold B.C. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology 214 1 (1995) 29-39
137. Trybala E., et al. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J. Virol. 74 19 (2000) 9106-9114
138. Schmidtke M., et al. Binding of a N,N′-bisheteryl derivative of dispirotripiperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families. Virology 311 1 (2003) 134-143
139. Ammendolia M.G., Marchetti M., and Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. Antiviral Res. 76 3 (2007) 252-262
140. el-Redwan R.M., and Tabll A. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J. Immunoassay Immunochem. 28 3 (2007) 267-277
141. Di Biase A.M., et al. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virol. 69 4 (2003) 495-502
142. Johansson C., et al. Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. J. Virol. 81 2 (2007) 954-963
143. Weng T.Y., et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 67 1 (2005) 31-37
144. Tinari A., et al. Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro. Int. J. Antimicrob. Agents 25 5 (2005) 433-438
145. Ammendolia M.G., et al. Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res. 73 3 (2007) 151-160
146. Saidi H., et al. Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J. Immunol. 177 8 (2006) 5540-5549
147. Puddu P., et al. Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. J. Leukoc. Biol. 82 2 (2007) 347-353
148. Oppenheim F.G., et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem. 263 16 (1988) 7472-7477
149. Pollock J.J., et al. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect. Immun. 44 3 (1984) 702-707
150. Wakabayashi H., et al. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 40 11 (1996) 821-825
151. Xu Y.Y., et al. In vitro susceptibility of Candida species to lactoferrin. Med. Mycol. 37 1 (1999) 35-41
152. Nikawa H., Samaranayake L.P., and Hamada T. Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch. Oral Biol. 40 6 (1995) 581-584
153. Nikawa H., et al. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch. Oral Biol. 38 12 (1993) 1057-1063
154. Valenti P., et al. Antifungal activity of ovotransferrin towards genus Candida. Mycopathologia 89 3 (1985) 169-175
155. Zarember K.A., et al. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J. Immunol. 178 10 (2007) 6367-6373
156. Viejo-Diaz M., Andres M.T., and Fierro J.F. Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob. Agents Chemother. 48 4 (2004) 1242-1248
157. Kuipers M.E., et al. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43 11 (1999) 2635-2641
158. Venkatesh M.P., et al. Prophylaxis with lactoferrin, a novel antimicrobial agent, in a neonatal rat model of coinfection. Adv. Ther. 24 5 (2007) 941-954
159. Yamaguchi H., Abe S., and Takakura N. Potential usefulness of bovine lactoferrrin for adjunctive immunotherapy for mucosal Candida infections. Biometals 17 3 (2004) 245-248
160. Leon-Sicairos N., et al. Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica. Biochem. Cell Biol. 84 3 (2006) 327-336
161. Ikadai H., et al. Inhibitory effect of lactoferrin on in vitro growth of Babesia caballi. Am. J. Trop. Med. Hyg. 73 4 (2005) 710-712
162. Tachezy J., et al. Tritrichomonas foetus: iron acquisition from lactoferrin and transferrin. Exp. Parasitol. 83 2 (1996) 216-228
163. Lehker M.W., and Alderete J.F. Iron regulates growth of Trichomonas vaginalis and the expression of immunogenic trichomonad proteins. Mol. Microbiol. 6 1 (1992) 123-132
164. Tanaka T., et al. The detection of bovine lactoferrin binding protein on Toxoplasma gondii. J. Vet. Med. Sci. 65 12 (2003) 1377-1380
165. Dzitko K., et al. Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin. Pol. J. Microbiol. 56 1 (2007) 25-32
166. Sinnis P., et al. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J. Exp. Med. 184 3 (1996) 945-954
167. Shakibaei M., and Frevert U. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J. Exp. Med. 184 5 (1996) 1699-1711
168. Cirioni O., et al. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J. Antimicrob. Chemother. 46 4 (2000) 577-582
169. Moore S.A., et al. Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution. J. Mol. Biol. 274 2 (1997) 222-236
170. Koradi R., Billeter M., and Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14 1 (1996) 51-55 29-32
171. Grover M., et al. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr. 86 3 (1997) 315-316